Institute for Health and Productivity Management, IHPM, Sean Sullivan

IHPM Conferences and Webinars:

REGISTER: Login to your current IHPM Account by clicking on the "Account Login" link on the top right of this page. If you do not already have an IHPM Online Account, please Click Here to Create One.

Founding Sponsor:

Click Each Title Individually to View the Complimentary COPD Webinar in one-hour segments

Chronic Obstructive Pulmonary Disease (COPD): The New Workplace "Epidemic"

Nature, Prevalence, Cost Impact & Management of COPD- Chan-Chou Chuang, MD - HealthCare Partners Medical Group

Economic Burden of COPD on Employers - William Bunn, MD, JD, MPH - Navistar International

Using Pay-for-Performance to Improve COPD Care - Guy D’Andrea - Discern Consulting

Employers’ Perspective on COPD and HEDIS Measurement - William Tulloch - NCQA

Click Here to
View a Complimentary Webinar Recording

Wellness and Health Improvement:

Programs that Increase Engagement & Sustain Behavior Change

Trane: Heidi Lattig, Director of Health & Productivity

Johnson & Johnson:

Fikry Isaac, MD, MPH - Exec. Dir., Global Health Services &

Jennifer Bruno - Worldwide Dir., Wellness & Health Promotion

Journal of Health and Productivity

> Back to JHP Titles

Assessing the Burden of Illness and Lost Work Productivity Associated with Frequent Disease Flares among Patients with Ulcerative Colitis

Susan C. Bolge, PhD;1 Heidi Waters, MS, MBA;1 Ahmad Naim, MD;1 Catherine Tak Piech, MBA1

1 Centocor Ortho Biotech Services, LLC, Horsham, PA, USA

References

1. The Merck Manuals Online Medical Library. Ulcerative Colitis. January 2007. http://www.merck.com/mmpe/sec02/ch018/ch018c.html#sec02-ch018-ch018c-1199 . Accessed January 28, 2009.

2. Karlinger K, Gyorke T, Mako E, Mester A, Tarjan Z. The epidemiology and the pathogenesis of inflammatory bowel disease. Eur J Radiol 2000;35(3):154-167.

3. Podolsky DK. Inflammatory Bowel Disease. N Engl J Med 2002; 347(6):417-429.

4. Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126(6):1504-1517.

5. Loftus CG, Loftus EV, Harmsen WS, Zinsmeister AR, Tremaine WJ, Melton LJ 3rd, et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis 2007;13(3):254-261.

6. Gibson TB, Ng E, Ozminkowski RJ, Wang S, Burton WN, Goetzel RZ, et al. The direct and indirect cost burden of Crohn's disease and ulcerative colitis. J Occup Environ Med 2008;50(11):1261-1272.

7. Bickston SJ, Waters HC, Dabbous O, Tang BI, Rahman MI. Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients. J Manag Care Pharm 2008;14(4):352-362.

8. Kappelman MD, Rifas-Shiman SL, Porter CQ, Ollendorf DA, Sandler RS, Galanko JA, et al. Direct healthcare costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology 2008;135(6):1907-1913.

9. Boonen A, Dagnelie PC, Feleus A, Hesselink MA, Muris JW, Stockbrugger RW, et al. The impact of inflammatory bowel disease on labor force participation: results of a population sampled case-control study. Inflamm Bowel Dis 2002;8(6):382-389.

10. Marri SR, Buchman AL. The education and employment status of patients with inflammatory bowel disease. Inflamm Bowel Dis 2005;11(2):171-177.

11. Longobardi T, Jacobs P, Bernstein CN. Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol 2003;98(5):1064-1072.

12. The “seven to eleven per year” category was missing from the survey due to programming error. Presumably, respondents from that category would have chosen either “three to six per year” or “one or more per month” depending on which more closely corresponded to their perceived frequency of flares. Therefore, whereas some level of sensitivity was lost, the measure should still adequately serve the purpose of analyzing relative differences in flares.

13. Prasad M, Wahlqvist P, Shikiar R, Shih YC. A review of self-report instruments measuring health-related work productivity: a patient-reported outcomes perspective. Pharmacoeconomics 2004;22(4):225-244.

14. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4(5):353-365.

15. US Bureau of Labor Statistics. May 2007 national occupational employment and wage estimates, United States. Available at: http://www.bls.gov/oes/2007/may/oes_nat.htm#b00-0000. Accessed April 22, 2009. Last updated February 12, 2009.

16. Gionchetti P, Rizzello F, Habal F, Morselli C, Amadini C, Romagnoli R, et al. Standard treatment of ulcerative colitis. Dig Dis 2003;21(2):157-167.

17. Valayos FS, Sandborn WJ. Positioning biologic therapy for Crohn's disease and ulcerative colitis. Curr Gastroenterol Rep 2007;9(6):521-527.

18. Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: Lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010;11:180–210.

19. Joyce JC, Waljee AK, Khan T, Wren PA, Dave M, Zimmermann EM, et al. Identification of symptom domains in ulcerative colitis that occur frequently during flares and are responsive to change in disease activity. Health Qual Life Outcomes 2008;6:69.

20. Rubin DT, Siegel CA, Kane SV, Binion DG, Panaccione R, Dubinsky MC, et al. Impact of ulcerative colitis from patients' and physicians' perspectives: results from the UC: NORMAL survey. Inflamm Bowel Dis 2009;15(4):581-588.

21. U.S. Census Bureau. Table 1128: Adult computer and adult internet users, by selected characteristics 1995 to 2006. In: Statistical Abstracts of the United States: 2008 (127th Edition). Washington, DC: Government Printing Office; 2008: 719.